Nkarta Begins Ntrust-1 Clinical Trial Of NKX019 In Lupus Nephritis, With The First Patient In Screening; Says IND Cleared For Ntrust-2
Portfolio Pulse from Benzinga Newsdesk
Nkarta has started the Ntrust-1 clinical trial for NKX019 in lupus nephritis and received FDA clearance for a second IND application for NKX019 in autoimmune diseases. The Ntrust-2 trial will target systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Clinical data from both trials are expected in 2025.
June 27, 2024 | 10:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nkarta has initiated the Ntrust-1 clinical trial for NKX019 in lupus nephritis and received FDA clearance for a second IND application for NKX019 in autoimmune diseases. The Ntrust-2 trial will focus on systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. Clinical data from both trials are expected in 2025.
The initiation of the Ntrust-1 trial and FDA clearance for the Ntrust-2 trial are significant milestones for Nkarta. These developments could positively impact the stock price in the short term due to increased investor confidence in the company's pipeline and regulatory progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100